CGRP Antagonists: A Growing Class for Migraine Prevention

CGRP (calcitonin gene‑related peptide) antagonists are a novel group of medications specifically designed to prevent migraine attacks by targeting a key neuropeptide involved in pain transmission and vascular regulation.

How CGRP Antagonists Work

These drugs either bind to the CGRP molecule or block its receptor, lowering CGRP levels in the nervous system. This reduces migraine‑related pain, aura, and other symptoms. They are effective for both chronic (≥15 headache days/month) and episodic migraine.

Approved CGRP Antagonists and Clinical Evidence

Fremanezumab (Ajovy)

A 2017 randomized trial showed that monthly or quarterly injections of fremanezumab significantly reduced headache days compared with placebo over 12 weeks in patients with chronic migraine.

Erenumab (Aimovig)

In the same year, a 6‑month study demonstrated that subcutaneous doses of 70 mg or 140 mg of erenumab lowered migraine frequency and improved daily functioning.

Eptinezumab (Vyepti)

A 2023 trial involving 800 adults with a history of 2–4 preventive treatment failures confirmed eptinezumab’s long‑term efficacy and tolerability as a preventive option.

Galcanezumab (Emgality)

A 2022 study reported that once‑monthly injections of galcanezumab effectively reduced monthly migraine headache days in episodic migraine patients and were well tolerated.

Rimegepant (Nurtec OTD)

In 2019, rimegepant achieved higher rates of pain‑free response and relief from the most bothersome symptom versus placebo. It is approved for both acute treatment and prevention.

Ubrogepant (Ubrelvy)

The 2019 trial found that ubrogepant provided rapid pain relief and symptom resolution within 2 hours, outperforming placebo.

Atogepant (Qulipta)

A 2021 study showed that once‑daily oral atogepant reduced migraine and headache days over a 12‑week period.

Zavegepant (Zavzpret)

In 2023, the nasal spray formulation of zavegepant was effective for acute migraine treatment with a favorable safety profile.

Safety, Side Effects, and Administration

Common adverse events are mild and include drowsiness, nausea, dry mouth, abdominal discomfort, and constipation (notably with Aimovig and Qulipta). Injection‑site pain or skin infection can occur; proper hand hygiene, site cleaning, and using a new needle each time reduce this risk.

Because CGRP also helps dilate blood vessels and regulate blood pressure, long‑term CGRP suppression may theoretically influence cardiovascular function. Ongoing research aims to clarify these potential risks.

Practical Considerations

Most CGRP antagonists are administered via self‑injection (monthly or quarterly), while rimegepant, atogepant, and zavegepant offer oral or nasal routes. Dosing schedules vary by product and individual response.

Future Directions

Research continues to explore long‑term safety, optimal sequencing with other preventives, and potential benefits for patients with multiple prior treatment failures. If you suffer from chronic or frequent migraines, discuss with your physician whether a CGRP antagonist could be part of your treatment plan.